Drug doses often warrant adjustment in obese patients.
Introduction
In Australia and internationally, approximately 30% of adults are obese, and 65% are either overweight or obese. 1, 2 There is little evidence and guidance on how best to dose these individuals.
Few studies have quantified the influence of body size on the pharmacokinetics or pharmacodynamics of many common drugs. 3 Generally, licensed dosing recommendations are based on clinical trials in which people with obesity are under-represented or excluded and evidence-based dosing guidelines are lacking. 3 This may result in arbitrary dose selection leading to therapeutic failure or drug toxicity.
A fixed strategy in which all patients receive the same dose remains a common form of drug dosing. However, significant variations in pharmacokinetic and pharmacodynamic responses can occur between patients due to weight, age, genetics, concurrent diseases and other factors. [4] [5] [6] [7] Ideally, the 'one dose fits all' paradigm should be replaced by individualised dosing methods.
Drug doses are usually calculated using a patient's total body weight. This is often inappropriate for obese patients, and clinicians may therefore dose using an alternative body size descriptor. Close monitoring of the patient's clinical response and therapeutic drug monitoring (if available) is important.
Drugs that commonly require dose adjustment in obese patients include low-molecular-weight heparins, 8 aminoglycoside antibiotics, 9 some anaesthetics, 10 monoclonal antibodies and chemotherapeutics.
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Body weight
Body size is typically defined using body mass index (BMI) ( Table 1) . 2 It is a poor dosing metric as comparable BMIs often represent dissimilar body Drug clearance represents the functional capacity of the body to metabolise and excrete a drug. Clearance is correlated to lean rather than adipose weight as adipose tissue has little metabolic activity. 12 As clearance determines a drug's maintenance dose, clinicians should consider how lean body weight, rather than total body weight, impacts dosing. When lean body weight increases there will be a corresponding increase in drug clearance and an increased dose may be required.
Commonly used weight-based drugs that may require dose adjustment and monitoring in obesity, and in particular morbid obesity, are listed in Table 2 . Individual drug monographs in the Australian Medicines Handbook should be consulted to identify if weight-based dosing is required.
Clearance has been correlated with lean body weight for opioids such as fentanyl, 10 anaesthetics such as propofol, 10 ranitidine, lithium and enoxaparin. 8 
Volume of distribution
Volume of distribution is related to structural aspects of the body. Hydrophilic drugs generally have a high plasma concentration relative to dose, and a smaller volume of distribution. In contrast, lipophilic drugs distribute more readily into adipose tissue, resulting in lower plasma concentrations and a larger volume of distribution. For lipophilic drugs, volume of distribution is more likely to correlate with total body weight. 6 Highly lipophilic drugs (phenytoin, midazolam, voriconazole, propofol) distribute extensively into adipose tissue, resulting in a larger volume of distribution compared to less lipophilic drugs.
Drugs with a large volume of distribution often require loading doses followed by a constant dose rate to maintain steady-state plasma concentrations. Steadystate concentrations are dependent on drug clearance.
Body size descriptors used to calculate drug doses
Several different body descriptors can be used to calculate drug doses (Table 3) .
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Total body weight
Using total body weight assumes that the pharmacokinetics of the drug are linearly scalable from normal-weight patients to those who are obese. This is inaccurate. For example, we cannot assume that a 150 kg patient eliminates a drug twice as fast as a 75 kg patient and therefore double the dose. Clinicians are alert to toxicities with higher doses, for example nephro-and neurotoxicity with some antibiotics and chemotherapeutics, and bleeding with anticoagulants. Arbitrary dose reductions or 'caps' are used to avoid these toxicities, but if too low can result in sub-therapeutic exposure and treatment failure. 6, 11, 12 Lean body weight Using a lean body weight metric encompasses a more scientific approach to weight-based dosing. Lean body weight reflects the weight of all 'non-fat' body components, including muscle and vascular organs such as the liver and kidneys. As lean body weight contributes to approximately 99% of a drug's clearance, 5 it is useful for guiding dosing in obesity.
This metric has undergone a number of transformations. The most commonly cited formula derived by Cheymol 7 is not optimal for dosing across body compositions and can even produce a negative result. A new formula has been developed (see Table 3 ) that appears stable across different body sizes, in particular the obese to morbidly obese. 15 A practical downfall of the calculation of lean body weight (and other body size descriptors) is the numerical complexity, which may not be palatable to a busy clinician. Often limited time is available for prescribing and an immediate calculation is required. Lean body weight calculators are available online, for example in the Therapeutic Guidelines. 17 
Adjusted body weight
Calculating doses based on adjusted body weight is mainly used for aminoglycoside antibiotics.
14 It was developed to account for adipose tissue, which does not affect drug clearance. A correction factor of 0.4 is used to estimate adjusted body weight ( Table 3 ). The aminoglycosides dose is then calculated using the resultant weight. This descriptor is rarely used in other drug classes, although there is some evidence for other antibiotics in the morbidly obese.
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Body surface area
Body surface area 16 is traditionally used to dose chemotherapeutics. It is a function of weight and height and has been shown to correlate with cardiac output, blood volume and renal function. However, it is controversial in patients at extremes of size because it does not account for varying body compositions. As a consequence, some older drugs such as cyclophosphamide, paclitaxel and doxorubicin were 'capped' (commonly at 2 m 2 ) potentially resulting in sub-therapeutic treatment. 11 Recent guidelines suggest that unless there is a justifiable reason to reduce the dose Table 3 Body size descriptors commonly used in drug dosing
Name Formula
Total body weight (kg) -Ideal body weight (kg) 
Unfractionated heparin
In thrombotic diseases, unfractionated heparin is dosed using total body weight. An initial bolus (units/kg) is followed by a continuous infusion (units/kg/hour) and adjusted based on the activated partial thromboplastin time (aPTT). However, nomograms often use a dose cap (bolus and maintenance) in obese patients. This can lead to undertreatment, and increased monitoring is recommended. Like enoxaparin, the prophylactic dose should be increased in morbid obesity, for example 5000 units three times a day or 7500 units twice daily.
Carvedilol, apixaban, ribavirin and prasugrel
Some drugs have a licensed dichotomised dose based on total body weight. The maximum daily dose of carvedilol is 50 mg in patients weighing less than 85 kg and 100 mg for patients weighing 85 kg or more. Consequently a patient weighing 86 kg would receive twice the dose of a patient weighing 84 kg. Dichotomised dose strategies can result in underand overdosing and should be used with caution in patients with obesity. Apixaban, ribavirin and prasugrel have similar dosing recommendations.
Cephazolin
Cephalosporins are often prescribed as surgical prophylaxis. Due to the increase in clearance in obese patients, the dose should be increased. 9 The recommended dose of 1 g has been increased to 2 g in obese patients to ensure adequate exposure and may need to be administered more frequently.
Conclusion
Estimating the optimal dose for obese patients is difficult and, in many cases, ill defined. Basing maintenance doses on total body weight is unlikely to result in a comparable drug response across different body sizes and generally increases the risk of adverse events. Individualised dosing based on the patient's lean body weight is recommended, with accompanying therapeutic drug monitoring and monitoring of the patient's clinical response.
Designing clinical trials that stratify doses across a range of body weights will improve drug-dosing knowledge. In the meantime, we need to rely on scientific principles to dose many drugs in the obese.
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(e.g. renal disease), total body weight should be used in the calculation of body surface area, until further research is done. 11 Little research into dosing based on body surface area has been conducted for other medicines.
Ideal body weight
Ideal body weight was developed for insurance purposes not for drug dosing. 13 It is a function of height and gender only and, like body surface area, does not take into account body composition. Using ideal body weight, all patients of the same height and sex would receive the same dose, which is inadequate and generally results in under-dosing. 4 For example a male who has a total body weight of 150 kg and a height of 170 cm will have the same ideal body weight as a male who is 80 kg and 170 cm tall. Both could potentially receive a mg/kg dose based on 65 kg (ideal body weight).
Calculating drug doses
The clinical issue is that calculating drug doses using each body size descriptor will result in a different weight. Consider dosing a 150 kg man who is 170 cm tall. Rounded to the nearest 5 kg, his body size descriptors are:
• total body weight = 150 kg Obviously, large variations exist for mg/kg dosing depending on which metric is used.
Enoxaparin
A pertinent example of this dilemma is enoxaparin, a hydrophilic anticoagulant. Its licensed dose for treatment of venous thromboembolism is based on total body weight (mg/kg). Many clinicians recognise that this results in high doses in obesity and increases the risk of toxicity, so they reduce or cap the dose (often at 100 mg) in patients over 100 kg. 18 This may result in sub-therapeutic anti-Xa concentrations, particularly in morbid obesity, as clearance increases with body size.
A dose based on lean body weight is warranted in this case and a dose of 1.5 mg/kg (lean body weight) has been proposed. 8 In the above example, the 150 kg male would receive 120 mg twice daily (rounded up), that is 1.5 x 80 kg.
The prophylactic dose is usually 20-40 mg daily. As clearance increases with body size, the dose should be increased in morbid obesity and suggested doses include 30-40 mg twice daily.
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